[
  {
    "topic": "pharmacology",
    "question": "In patients with rectal cancer, what is the standard neo-adjuvant treatment to improve sphincter preservation?",
    "options": [
      "CROSS regimen",
      "Trastuzumab plus paclitaxel",
      "FOLFOX",
      "5-FU with radiation"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a common limitation of neo-adjuvant therapy?",
    "options": [
      "Potential delay in surgery due to toxicity",
      "Tumor heterogeneity leading to mixed response",
      "Tumor progression in non-responders",
      "High levels of treatment adherence"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Adjuvant therapy should ideally be started within what time frame after surgery?",
    "options": [
      "Immediately post-op",
      "Within 24 hours",
      "After 12 weeks",
      "3\u20138 weeks"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a goal of adjuvant therapy?",
    "options": [
      "Eradication of micrometastases",
      "Elimination of visible tumor burden",
      "Enhancement of overall survival",
      "Improvement of disease-free survival"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which drug class used in adjuvant chemotherapy works by DNA intercalation and inhibition of topoisomerase II?",
    "options": [
      "Anthracyclines",
      "Antimetabolites",
      "Taxanes",
      "Alkylating agents"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Adjuvant therapy is LEAST likely to be beneficial in which of the following cancers?",
    "options": [
      "Renal cell carcinoma",
      "Lung cancer",
      "Breast cancer",
      "Colorectal cancer"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which patient factor is LEAST relevant when individualizing adjuvant chemotherapy?",
    "options": [
      "Tumor molecular markers",
      "Personal income level",
      "Performance status",
      "Organ function"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a clinical benefit of neo-adjuvant therapy?",
    "options": [
      "Facilitates margin-positive resections",
      "Avoids the need for chemotherapy post-surgery",
      "Enables organ preservation in selected cancers",
      "Requires fewer drug cycles than adjuvant therapy"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Neoadjuvant therapy is primarily indicated for which of the following purposes?",
    "options": [
      "To treat cancer recurrence",
      "To provide palliative symptom control",
      "To eliminate residual disease after surgery",
      "To reduce tumor size before definitive surgery"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which is a major pharmacological challenge in adjuvant therapy?",
    "options": [
      "Increased tumor vascularity",
      "Low patient compliance",
      "Lack of imaging sensitivity",
      "Drug resistance and tumor heterogeneity"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which is NOT typically a factor guiding the selection of adjuvant therapy?",
    "options": [
      "Tumor visibility on imaging",
      "Tumor histology",
      "Patient's genetic polymorphisms",
      "Molecular markers"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following biomarkers can be used to monitor response to neoadjuvant therapy?",
    "options": [
      "CEA",
      "LDL cholesterol",
      "HbA1c",
      "CRP"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following drugs acts by stabilizing microtubules and inhibiting mitosis?",
    "options": [
      "Methotrexate",
      "Cyclophosphamide",
      "Paclitaxel",
      "5-FU"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which principle supports the use of multiple cycles in adjuvant chemotherapy?",
    "options": [
      "First-order log-kill hypothesis",
      "Gompertzian model of drug clearance",
      "Zero-order drug kinetics",
      "Mendelian inheritance model"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a typical side effect concern for adjuvant therapy?",
    "options": [
      "Infertility",
      "Neuropathy",
      "Myelosuppression",
      "Enhanced immunity"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "What best describes the mechanism of action of platinum-based chemotherapeutic agents?",
    "options": [
      "Topoisomerase inhibition",
      "DNA cross-linking",
      "Estrogen receptor blockade",
      "Microtubule stabilization"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which is NOT a rationale for neoadjuvant therapy?",
    "options": [
      "Improving postoperative recovery speed",
      "Tumor downstaging",
      "Assessment of chemosensitivity",
      "Early clearance of micrometastases"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following best explains the log-kill hypothesis in chemotherapy?",
    "options": [
      "Each dose kills a constant fraction of tumor cells",
      "All tumor cells die in the first cycle",
      "Tumor cells die only when oxygenated",
      "Each dose kills a fixed number of cells"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following best defines adjuvant therapy in cancer care?",
    "options": [
      "Any treatment given after surgery when no visible tumor remains",
      "A substitute for definitive surgical treatment",
      "A therapy used to shrink tumors before surgery",
      "A palliative intervention aimed at symptom control"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which combination regimen is commonly used in breast cancer adjuvant therapy?",
    "options": [
      "FOLFOX",
      "CMF (Cyclophosphamide + Methotrexate + 5-FU)",
      "CROSS",
      "MAP"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following cancers commonly uses the CROSS regimen in neo-adjuvant therapy?",
    "options": [
      "Esophageal cancer",
      "Osteosarcoma",
      "Breast cancer",
      "Colorectal cancer"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following combinations is a typical adjuvant regimen used in stage III colorectal cancer?",
    "options": [
      "CMF",
      "AC-T",
      "CROSS",
      "FOLFOX"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following BEST explains the importance of tumor vascularity in neo-adjuvant therapy?",
    "options": [
      "It enhances tumor immune evasion",
      "It determines radiation sensitivity",
      "It allows better drug delivery and efficacy",
      "It increases genetic polymorphism"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is the BEST surrogate marker of successful neoadjuvant therapy in breast cancer?",
    "options": [
      "Tumor vascularity",
      "Reduction in CEA levels",
      "Pathologic complete response (pCR)",
      "Resolution of clinical symptoms"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "What is the definition of 'major pathologic response' (MPR) in neo-adjuvant therapy?",
    "options": [
      "Complete absence of tumor cells in the tissue",
      "Elimination of circulating tumor cells",
      "Reduction in tumor size on imaging by 50%",
      "Presence of less than 10% residual tumor cells"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "The main pharmacological rationale behind the need for combination chemotherapy in adjuvant settings is:",
    "options": [
      "To minimize cost of therapy",
      "To shorten treatment duration",
      "To overcome resistance and tumor heterogeneity",
      "To reduce surgical complications"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which statement about the timing of adjuvant therapy is CORRECT?",
    "options": [
      "Timing does not affect treatment outcome",
      "Initiation beyond 8 weeks may reduce efficacy",
      "It is contraindicated within 6 weeks of surgery",
      "It is effective even when started after 12 weeks post-op"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following drugs is a hormonal agent used in adjuvant therapy of ER+ breast cancer?",
    "options": [
      "Capecitabine",
      "Tamoxifen",
      "Paclitaxel",
      "Doxorubicin"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is FALSE regarding the use of neoadjuvant therapy in NSCLC?",
    "options": [
      "Improves operability in bulky tumors",
      "Used in select Stage II and IIIA tumors",
      "Guarantees pathological complete response",
      "Improves mediastinal nodal clearance"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which tumor type benefits from the use of the MAP regimen as neoadjuvant chemotherapy?",
    "options": [
      "Breast cancer",
      "Lung cancer",
      "Osteosarcoma",
      "Colorectal cancer"
    ],
    "correct_option": 2
  }
]
